Using the Chinese herb Scutellaria barbata against extensively drug-resistant Acinetobacter baumannii infections: in vitro and in vivo studies.
Using the Chinese herb Scutellaria barbata against extensively drug-resistant Acinetobacter baumannii infections: in vitro and in vivo studies.
复制标题
DOI：
10.1186/s12906-018-2151-7
复制
发表时间：
2018-03-20
影响因子：
--
通讯作者：
Wang JL
中科院分区：
文献类型：
--
作者：
Tsai CC;Lin CS;Hsu CR;Chang CM;Chang IW;Lin LW;Hung CH;Wang JL
尚未进行动物模型研究来测试草药化合物对多重耐药鲍曼不动杆菌感染的功效。很少有抗生素可用于治疗由广泛耐药鲍曼不动杆菌 (XDRAB) 引起的肺部感染。为了寻找替代疗法，对传统中草药的抗菌潜力进行了筛选。本研究筛选了30种台湾传统使用且常用于清热解毒的草药。通过纸片扩散试验、时间杀灭试验和小鼠肺部感染模型对具有抗菌活性的草药进行了分析。在测试的 30 种草药中，只有半枝莲显示出 100% 的体外抗 XDRAB 活性。此外，我们将半枝莲提取物与粘菌素的抗菌效果进行了比较，发现半枝莲提取物表现出更好的抗菌效果。在 XDRAB 肺炎小鼠模型中，我们比较了口服半枝莲提取物（200 mg/kg，每 24 小时）、气管内施用粘菌素（75,000 U/kg，每 12 小时）和对照组的抗菌效果。与对照组肺部相比，接受口服半枝莲提取物的治疗组肺部细菌负荷显着降低。此外，组织病理学检查还显示，口服半枝莲提取物治疗组的血管周围、支气管周围和肺泡炎症得到了更好的解决。我们来自动物模型的体外和体内数据支持使用半枝莲作为治疗 XDRAB 肺部感染的替代药物。然而，需要详细的动物研究和临床试验来确定半枝莲治疗 XDRAB 肺部感染的临床效用。
No animal model studies have been conducted in which the efficacy of herbal compounds has been tested against multidrug-resistant Acinetobacter baumannii infections. Very few antibiotics are available for the treatment of pulmonary infections caused by extensively drug-resistant Acinetobacter baumannii (XDRAB). To find alternative treatments, traditional Chinese herbs were screened for their antimicrobial potential. The present study screened 30 herbs that are traditionally used in Taiwan and that are commonly prescribed for heat clearing and detoxification. The herbs with antibacterial activities were analysed by disc diffusion assays, time-kill assays and a murine lung infection model. Of the 30 herbs tested, only Scutellaria barbata demonstrated 100% in vitro activity against XDRAB. Furthermore, we compared the antibacterial effect of the S. barbata extract with that of colistin, and the S. barbata extract showed better antibacterial effect. In the XDRAB pneumonia murine model, we compared the antimicrobial effects of the orally administered S. barbata extract (200 mg/kg, every 24 h), the intratracheally administered colistin (75,000 U/kg, every 12 h), and the control group. The bacterial load in the lungs of the treatment group that received the oral S. barbata extract showed a significant decrease in comparison to that in the lungs of the control group. In addition, histopathological examinations also revealed better resolution of perivascular, peribronchial, and alveolar inflammation in the oral S. barbata extract-treated group. Our in vitro and in vivo data from the animal model support the use of S. barbata as an alternate drug to treat XDRAB pulmonary infections. However, detailed animal studies and clinical trials are necessary to establish the clinical utility of S. barbata in treating XDRAB pulmonary infections.
登录
查看更多内容
影响因子：
3.7
作者：
Miyasaki, Yoko;Rabenstein, John D.;Liu, George Y.
通讯作者：
Liu, George Y.
影响因子：
5.4
作者：
Chao, Te-Hsin;Fu, Pin-Kuei;Lin, Ching-Heng
通讯作者：
Lin, Ching-Heng
影响因子：
0.6
作者：
Tang, Qi-Ling;Kang, Ai-Rong;Lu, Cong-Xiao
通讯作者：
Lu, Cong-Xiao
影响因子：
2.6
作者：
Tiwari, Monalisa;Roy, Ranita;Tiwari, Vishvanath
通讯作者：
Tiwari, Vishvanath
影响因子：
3.8
作者：
Perez, Alejandra T.;Arun, Banu;Shapiro, Charles L.
通讯作者：
Shapiro, Charles L.